Researchers have identified 26 new genes that are linked to intellectual disabilities.
According to researchers, alcohol use disorder poses an increased risk for the early development of dementia.
Sustained use of the antipsychotic olanzapine resulted in potentially adverse alterations in brain structure, specifically cortical thinning.
Alzheimer's risk is increased for those with anosognosia, a condition in which sufferers are unaware they are experiencing memory loss.
According to researchers, 40% of people with treatment resistant depression who received rTMS no longer had suicidal thoughts following treatment.
Repetitive transcranial magnetic stimulation helped reduce cannabis use by up to 60% in those with schizophrenia who have cannabis use disorder.
A new study reports sub-groups of people use their brains differently when imitating emotional faces. For those with schizophrenia, researchers found no categorically different social brain functions than those without the condition, but do fall into different sub-groups that respond to different types of treatments.
While cannabis users reported more psychotic experiences than non-users generally, the effect was more pronounced in those with a genetic risk factor for schizophrenia.
Amiloride, a common blood pressure medication, shows potential in treating anxiety disorder and pain when administered in nebulized form, researchers report.
People diagnosed with mental health disorders are more likely to report poor sleep quality, including sleep disturbances and problems falling back to sleep, than the general population.
Researchers have developed new therapeutic molecules that appear to assist in reversing memory loss associated with depression and aging.
A new study reports those who suffer from persistent depression lasting more than ten years have higher levels of neuroinflammation.
